Quoin Pharmaceuticals, Ltd. (QNRX)
- Previous Close
0.6256 - Open
0.6060 - Bid --
- Ask --
- Day's Range
0.6060 - 0.6390 - 52 Week Range
0.4770 - 6.1800 - Volume
14,318 - Avg. Volume
2,626,257 - Market Cap (intraday)
3.154M - Beta (5Y Monthly) 1.89
- PE Ratio (TTM)
-- - EPS (TTM)
-3.6600 - Earnings Date Nov 7, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
4.50
Quoin Pharmaceuticals, Ltd., a clinical stage specialty pharmaceutical company, focuses on the development and commercialization of therapeutic products for rare and orphan diseases. Its lead product is QRX003, a topical lotion to treat Netherton Syndrome (NS). The company is also developing QRX004 for the treatment of recessive dystrophic epidermolysis bullosa; QRX007 to treat NS; and QRX008 for the treatment of scleroderma. It has a research agreement with Queensland University of Technology; a license agreement with Skinvisible Inc.; consulting agreements with Axella Research LLC; and a Master Service Agreement with Therapeutics Inc. The company was founded in 2018 and is based in Ashburn, Virginia. Quoin Pharmaceuticals, Ltd. operates as a subsidiary of Skinvisible, Inc.
quoinpharma.comRecent News: QNRX
View MorePerformance Overview: QNRX
Trailing total returns as of 11/21/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: QNRX
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: QNRX
View MoreValuation Measures
Market Cap
3.16M
Enterprise Value
-7.15M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
--
Price/Book (mrq)
0.58
Enterprise Value/Revenue
--
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-36.32%
Return on Equity (ttm)
-100.03%
Revenue (ttm)
--
Net Income Avi to Common (ttm)
-8.28M
Diluted EPS (ttm)
-3.6600
Balance Sheet and Cash Flow
Total Cash (mrq)
12.57M
Total Debt/Equity (mrq)
43.11%
Levered Free Cash Flow (ttm)
-5.05M